Discovery and impact of Bedaquiline after 10 years of regulatory approval
Professor Koul will discuss his key involvement in the discovery and development of bedaquiline – the first drug to be approved in the last 45 years for the treatment of drug-resistant tuberculosis.
Professor Koul will discuss his key involvement in the discovery and development of bedaquiline – the first drug to be approved in the last 45 years for the treatment of drug-resistant tuberculosis. Bedaquiline has been conditionally approved in over 64 countries and has reached more than 600,000 TB patients across the world. It is on WHO’s list of ‘essential medicines’ both for adult as well as pediatric TB. He will provide an overview of the last 10 years of bedaquiline use in the clinic as well as discuss the potential future of this life-changing drug.
Speaker
Professor Anil Koul
Professor Anil Koul is currently Vice-President and Head of Discovery Research at Global Public Health R&D Unit of Johnson and Johnson. He is an adjunct Professor of Translation Discovery at London School of Hygiene and Tropical Medicine (LSHTM), where he has established a laboratory focused on translational medicine for tuberculosis. Prof Koul has published in several leading scientific journals, including Nature and Science, and holds more than 30 international patents.
Event notices
- Please note that you can join this event in person or you can join the session remotely.
- Please note that the recording link will be listed on this page when available.
Admission
Contact
